Failure to Maintain a Suppressed Level of Serum Testosterone during Long-Acting Depot Luteinizing Hormone-Releasing Hormone Agonist Therapy in Patients with Advanced Prostate Cancer

Publisher： Karger

E-ISSN： 1423-0399|77|2|135-138

ISSN： 0042-1138

Source： Urologia Internationalis, Vol.77, Iss.2, 2006-08, pp. : 135-138

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Clinical Effect of Switching from a Luteinizing Hormone-Releasing Hormone Agonist to an Antagonist in Patients with Castration-Resistant Prostate Cancer and Serum Testosterone Level ≥ 20 ng/dl

By  

Current Urology, Vol. 9, Iss. 1, 2015-0 ,pp. : 31-35

Karger

Access to resources Recommend Favorite

Non‐steroidal antiandrogen monotherapy compared with luteinizing hormone‐releasing hormone agonists or surgical castration monotherapy for advanced prostate cancer: a Cochrane systematic review

By  

BJU INTERNATIONAL, Vol. 116, Iss. 1, 2015-07 ,pp. : 30-36

John Wiley & Sons Inc

Access to resources Recommend Favorite

Comparison of LH-RH Analogue 1-Month Depot and 3-Month Depot by Their Hormone Levels and Pharmacokinetic Profile in Patients with Advanced Prostate Cancer

By  

Urologia Internationalis, Vol. 60, Iss. 1, 1998-03 ,pp. : 9-17

Karger

Access to resources Recommend Favorite

Optimal Starting Time for Flutamide to Prevent Disease Flare in Prostate Cancer Patients Treated with a Gonadotropin-Releasing Hormone Agonist

By  

Urologia Internationalis, Vol. 66, Iss. 3, 2001-04 ,pp. : 135-139

Karger

Access to resources Recommend Favorite

Long-acting testosterone undecanoate for parenteral testosterone therapy

By Yassin Aksam A   Huebler Doris   Saad Farid  

Therapy, Vol. 3, Iss. 6, 2006-11 ,pp. : 709-721

Future Medicine

Access to resources Recommend Favorite